Senseonics (SENS)
Develops implantable Eversense systems for long-term glucose monitoring in adults with diabetes.
$9.89
vs last close+0.11 (+1.07%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 8 | 5 | 5 | 4 | 8 | 6 | 7 | 8 | 14 | 12 | 14 |
| Cost of revenue | 5 | 7 | 5 | 5 | 8 | 4 | 5 | 4 | 5 | 7 | 5 | 6 |
| Gross profit | 1 | 1 | 0 | 0 | −4 | 4 | 2 | 3 | 3 | 8 | 7 | 9 |
| 20 | 18 | 19 | 20 | 19 | 18 | 15 | 17 | 23 | 29 | 39 | 45 | |
| Research & development | 13 | 11 | 10 | 11 | 11 | 9 | 7 | 8 | 8 | 9 | 9 | 12 |
| Selling, general & administrative | 7 | 7 | 8 | 9 | 8 | 9 | 8 | 10 | 15 | 20 | 30 | 33 |
| Operating income | −19 | −17 | −18 | −19 | −23 | −14 | −13 | −14 | −20 | −21 | −32 | −36 |
| −5 | 0 | −1 | −1 | −1 | −1 | −1 | 0 | 0 | 0 | 0 | −1 | |
| Interest income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest expense | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 |
| Other non-operating income | 3 | −2 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 |
| Income before tax | −24 | −17 | −19 | −20 | −24 | −15 | −14 | −15 | −20 | −21 | −32 | −37 |
| Net income from continuing operations | −24 | −17 | −19 | −20 | −24 | −15 | −14 | −15 | −20 | −21 | −32 | −37 |
| Net income | −24 | −17 | −19 | −20 | −24 | −15 | −14 | −15 | −20 | −21 | −32 | −37 |
| EPS, basic | −$0.81 | −$0.65 | −$0.61 | −$0.66 | −$0.77 | −$0.46 | −$0.40 | −$0.52 | −$0.43 | −$0.50 | −$0.71 | −$0.63 |
| EPS, diluted | −$0.81 | −$0.65 | −$0.61 | −$0.66 | −$0.77 | −$0.46 | −$0.40 | −$0.52 | −$0.43 | −$0.50 | −$0.71 | −$0.63 |
| Weighted average shares, basic | 30 | 27 | 31 | 31 | 31 | 33 | 36 | 30 | 45 | 42 | 46 | 58 |
| Weighted average shares, diluted | 30 | 27 | 31 | 31 | 31 | 33 | 36 | 30 | 45 | 42 | 46 | 58 |
| EBITDA | −21 | −15 | −17 | −18 | −22 | −13 | −12 | −13 | −18 | −19 | −31 | −35 |
| Depreciation & amortization | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| EBIT | −22 | −15 | −17 | −18 | −22 | −13 | −13 | −13 | −18 | −20 | −31 | −35 |
